Posted
Apr 09 2008, 08:50 PM
by
Dave Dispennette
The Playbook 100
ERES @ $12.65 (Eresearch Technology) offers cardiac clinical trial management software for pharmaceutical companies and clinical research organizations. Earnings are expected to grow 42% this year and another 30% in 2009. Institutional sponsorship has steadily increased from 39 to 51 funds owning a position in the stock over the last year and we are looking to ride their coattails higher. We are establishing half a position here and will enter the remaining half on a pull back to $11.50 or a move above $13. Our stop loss will be set at $10.75.
TC @ $21.43 (Thompson Creek Metals) is a Canadian producer of Molybdenum and other precious metals from mines in Canada and the U.S. Earnings are expected to grow 102% this year and another 59% in 2009 to $4 a share. We are establishing a position here and will set our stop loss at $18.
This newsletter has been sent to you for informative purposes only and in no event should be construed as a representation by The Stock Playbook or its employees as an offer to sell or solicitation of an offer to buy any securities. The factual information given is taken from sources we believe to be reliable, but is not guaranteed as to its accuracy or completeness. The opinions expressed should be given only such weight as opinions warrant. employees and/or family members may have a position in the securities mentioned and may make purchase and/or sales of such securities from time to time in the open market or otherwise Recipients of The Stock Playbook prohibited from, directly or indirectly, distributing, forwarding , plagiarizing or copying any part of this message without expressed written consent from The Stock Playbook. Some content may have been based, at least in part, on material gathered from Investor's Business Daily ® and/or YAHOO!®